Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Indian J Pediatr. 2010 Mar;77(3):263-6. doi: 10.1007/s12098-010-0035-z. Epub 2010 Feb 22.
To evaluate the efficacy of clobazam in childhood refractory epilepsy and to characterize the adverse drug reaction profile in the Indian population.
A cohort of 88 children with 'refractory' epilepsy was started on clobazam as add-on therapy. Diagnosis was established and seizure type recorded. Therapeutic response was recorded as 'complete', 'good', and 'no response'. Observed side effects were classified as 'mild', 'moderate' and 'severe'.
Most children were on at least two antiepileptics. Seizures most identified were either partial (36.3%) or generalized tonic-clonic (15.9%). The dose ranged from 0.3-2 mg/kg/day (average 1+0.2 mg/kg/day). Clobazam was effective against all seizure types with complete seizure control seen in 60.2% patients. Tolerance was seen in 5 (5.6%) patients. Side effects were seen in 23 (26%) patients and were 'mild' in 20 (86.9%) of them. Clobazam was stopped in three patients who developed ataxia, which resolved on stopping the drug.
Clobazam was observed to be an effective broad-spectrum antiepileptic with 'mild' side effects in Indian children.
评估氯巴占在儿童难治性癫痫中的疗效，并描述其在印度人群中的不良反应特征。
对 88 名“难治性”癫痫儿童进行氯巴占的附加治疗，记录诊断和发作类型。将治疗反应分为“完全”、“良好”和“无反应”。观察到的不良反应分为“轻微”、“中度”和“严重”。
大多数儿童至少服用了两种抗癫痫药物。最常见的发作类型是部分发作（36.3%）或全面强直阵挛发作（15.9%）。剂量范围为 0.3-2 mg/kg/日（平均 1+0.2 mg/kg/日）。氯巴占对所有发作类型均有效，60.2%的患者完全控制了发作。5 名（5.6%）患者出现了耐受性。23 名（26%）患者出现了不良反应，其中 20 名（86.9%）为“轻微”。有 3 名患者因出现共济失调而停止使用氯巴占，停药后症状缓解。
氯巴占在印度儿童中观察到是一种有效且广谱的抗癫痫药物，其不良反应轻微。
